. 2018 Nov 12;29(12):2787–2793. doi: 10.1681/ASN.2018070741

Table 1.

AKI and CKD events identified in retrospective analysis of administrative databases that compared warfarin with a novel oral anticoagulant in patients with atrial fibrillation

Ref. and Patient No.	Treatment^a	AKI Rate^b	Hazard Ratio^c
Ref. and Patient No.	Treatment^a	AKI Rate^b	AKI^d	CKD^d
Chan et al.²⁶
>20,000 (total)	Warfarin	CKD² (6.8 to 26.0)	NR	NR
	Warfarin	No CKD (2.0 to 6.2)	NR	NR
	Dabigatran	CKD (2.9 to 3.95)	0.62 (0.49 to 0.77)	NR
	Dabigatran	No CKD (1.7 to 2.6)	0.56 (0.46 to 0.69)	NR
Yao et al.²³
9769	Warfarin	10.3	0.69 to 0.84	0.46 to 0.88
	All NOACs	5.9 to 9.2
Shin et al.²⁷
6412	Warfarin	9.49
	All NOACs	7.5	0.79 (0.68 to 0.92)	NR

These studies did not take into account whether coagulopathy (international normalized ratio >3.0 or significant bleeding) was present when the AKI was identified. NR, not reported; NOAC, novel oral anticoagulant.

At baseline.

AKI events per year shown as 95% confidence interval (Chan et al.²⁶), AKI rate per year of follow-up (Chan et al.,²⁶ Yao et al.,²³ and Shin et al.²⁷), or hazard ratio (Chan et al.,²⁶ Yao et al.,²³ and Shin et al.²⁷).

Hazard ratios calculated as AKI or CKD in patients on NOAC/patients on warfarin. All hazard ratios were significantly <1.0 except for the ARISTOTLE trial.

Variously defined (e.g., on-treatment eGFR decline >20%–30% per year).